Track the Chordia Therapeutics株式会社 stock price and the full insider trade history of the company, a listed issuer based in Japan. Shares are quoted on the JP market, under the authority of EDINET (Japan FSA). Market capitalisation: €122.7bn. The latest transaction was filed on 22 May 2026 (Holding update). Among the most active insiders: SBI Investment Co., Ltd.. Every trade is free.
29
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
24Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,524 of 28,832 companies
7.5
score / 100
Value
8
Quality
7
FCF yld-30%
Earn yld-29%
EV/EBITDA·
ROE-56%
Gross mgn-6.6%
Net mgn-8.3%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Chordia Therapeutics is a company listed on the XTKS market, specializing in the development of innovative therapies. It focuses on research and commercialization of treatments for various diseases.